Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the globa...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Br J Haematol
المؤلفون الرئيسيون: Kumar, Shaji, Moreau, Philippe, Hari, Parameswaran, Mateos, Maria‐Victoria, Ludwig, Heinz, Shustik, Chaim, Masszi, Tamas, Spencer, Andrew, Hájek, Roman, Romeril, Kenneth, Avivi, Irit, Liberati, Anna M., Minnema, Monique C., Einsele, Hermann, Lonial, Sagar, Berg, Deborah, Lin, Jianchang, Gupta, Neeraj, Esseltine, Dixie‐Lee, Richardson, Paul G.
التنسيق: Artigo
اللغة:Inglês
منشور في: John Wiley and Sons Inc. 2017
الموضوعات:
Haematological Malignancy
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574012/
https://ncbi.nlm.nih.gov/pubmed/28485007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14733
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة